Friday, 29 October 2021
Investor Ideas #Potcasts 609, #Cannabis News and #Stocks on the Move; (OTCQB: $PHOT), (CSE: $BCBC.C), (NASDAQ: $ACB), (CSE: $CURA.C) (OTCQX: $CURLF)
Investor Ideas #Potcasts
609, #Cannabis News and #Stocks on the Move; (OTCQB: $PHOT), (CSE: $BCBC.C),
(NASDAQ: $ACB), (CSE: $CURA.C) (OTCQX: $CURLF)
Delta, Kelowna, BC, October 29, 2021 (Investorideas.com
Newswire) www.Investoride, as.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast
edition of cannabis news and
stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/102921-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/10291PHOT-BCBC-ACB-CURA-CURLF.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In today’s podcast
we look at a few public company announcements.
Curaleaf
Holdings, Inc. (CSE:
CURA) (OTCQX:
CURLF), a leading international provider of consumer
products in cannabis, announced
earlier this week that its initial batches of New York whole
flower have cleared testing by third party labs and that sales of three initial
strains began this week with the Company's Newburgh location followed by
Curaleaf's Carle Place, Forest Hills, and Plattsburgh dispensaries.
"Our patients have been waiting
a long time for this day and we couldn't be happier to be able to deliver whole
flower product to all four of our New York locations in the next day or so and
to the majority of our wholesale partners within the month," said Joe
Bayern, CEO of Curaleaf. "Fortunately, we have been preparing for this
moment and we are more than ready with plenty of product for all our New York
locations. We are grateful to Governor Hochul and the OCM for moving this
forward so quickly, and we look forward to robust sales and happy customers. We
appreciate the patience and loyalty of all our patients as we worked toward
this milestone."
Prior to this month, cannabis was
only available to New York patients in ground form, a source of frustration for
many patients who prefer the plant's medicinal applications in its purest and
most natural format.
Curaleaf whole flower will also be
available to the majority of the Company's wholesale partners in the state by
the end of the month, ensuring that the Company maintains its position as the
New York market leader and its product will be available throughout the state.
Aurora
Cannabis Inc. (NASDAQ:
ACB)
(TSX:
ACB),
earlier this week, announced a
manufacturing agreement with The Valens
Company Inc., a leading manufacturer of cannabis products, to manufacture a
new seasonal offering in the mint category.
Launching under Drift Turbo, the Company's mainstream adult-use recreational brand,
the new Canna Cane Mints are a two-piece hard peppermint candy containing 10mg
THC (5mg THC per piece). This is the first product offering under the
manufacturing arrangement, which is expected to expand in the coming months.
"We know that Canadian cannabis
consumers are looking for novelty and variety, and seasonal offerings are a key
approach to strategically expanding our portfolio of adult-use products,"
said Miguel Martin, CEO, Aurora Cannabis. "Valens' exceptional
manufacturing capabilities complement our product line up this upcoming holiday
season. Our strategic relationship is designed to unlock efficiencies as we
seek to bring innovation to market with speed and differentiation that connects
with consumers."
The cannabis edibles will be
manufactured using SōRSE™ by Valens
emulsion technology, a patented, in-house emulsion technology that transforms
cannabis oils into water-soluble forms to infuse foods, liquids and topicals
without the taste or smell of cannabis.
Tyler Robson, Chief Executive
Officer, Co-Founder and Chair of The Valens Company, said, "This is an
important milestone for the Canadian cannabis market as two of the largest companies
in this sector come together. We have admired Aurora for their leadership and
continuing to elevate and challenge industry standards. Our companies share the
same ethos when it comes to bringing the highest quality products to market and
offering a premium experience to consumers."
Aurora's upcoming holiday portfolio
will also include a new 510 vape cartridge launching under the Company's
adult-use recreational brand, Daily Special. The new Cranberry Sauce 1g 510
Vape is a high-THC distillate vape and is infused with the classic sweet-tart
flavour of festive cranberries. Both the Canna Cane Mints and Cranberry Sauce
Vape are limited-time products and will be available for purchase in British
Columbia and Alberta beginning in November. The Cranberry Sauce 1g 510 Vape
will also be available for purchase in the Maritimes.
The
BC Bud Corporation (CSE:
BCBC), a house of high-quality cannabis brands based out of
British Columbia, Canada,
announced a partnership between its in-house craft concentrate
brand, Solventless Solutions, and micro-cultivator Habitat's certified organic
flower brand, Cake and Caviar.
An industry leading partnership, a
first of its kind in Canada, Solventless Solutions will work in tandem with
Habitat's Cake and Caviar to produce farm-to-table premium solventless extracts
using meticulously selected cultivars to be flash frozen immediately after
harvest. Through this innovative collaboration, Solventless Solutions will be
the industry's premium destination for small-scale, chemical-free extraction
with the ability to process biomass from micro-cultivators.
Engaging in the partnership with
Habitat as a superior top shelf flower producer creates a seamless conduit for
Solventless Solutions to begin bringing craft concentrates to the market. The
Company will release concentrates under its house of brands, allowing for the
building and strengthening of new infrastructure and continued relationships
with cultivators. This will also allow the continual research and dynamic development
for Habitat's growing genetic lineup.
"Working with the team at
Solventless Solutions, we are excited to add top shelf rosin products to our
portfolio utilizing our unique genetics. Partnering with experts is crucial in
order for Habitat to continue with its existing micro operations around
cultivation, research and development thus we are grateful for the opportunity
to expand alongside this talented team" commented Rudi Schiebel, CEO of
Habitat.
"The partnership between
Solventless Solutions and Habitat is the first of its kind in the country, and
marks a key pivot point in our mission to expand The BC Bud Co within the
evolving cannabis industry," said The BC Bud Co CEO Brayden Sutton.
"This exciting collaboration is key to our brand focused strategy as we
continue to focus on maximizing shareholder value through relationships and
partnerships."
GrowLife,
Inc. (OTCQB:
PHOT), one of the nation’s most recognized indoor
cultivation product and service providers, announced that it
has entered into an exclusive distribution agreement with the leading mushroom
cultivation equipment supplier in Canada, My
Fungi Inc., whereas the Company will have the exclusive right to market and
distribute its proprietary line of mushroom cultivation equipment throughout
the United States. This marks the Company’s entrance into the expanding
mushroom industry, servicing both B2B and B2C customers, by supplying
hard-to-find essential equipment for mushroom cultivation.
Mushroom cultivation has seen a
significant spike in growth in recent years, with consumer demand for specialty
mushrooms for food, wellness, nutraceutical, and medical purposes exploding.
Mushroom cultivation is extremely specialized and requires specialized
equipment to produce at large-scale. As a leader in cultivation equipment for
the cannabis industry, GrowLife’s progression into offering these products
through its robust network of hydroponic and ecommerce sellers is natural and
aligns with the core competencies of the Company. By offering items such as
liquid culture, blended and sterile substrates, and all in one kits, GrowLife
is now positioned to address the demand for these products throughout the US,
through a consistent supply chain created through the agreement with My Fungi.
“Moving into the mushroom
cultivation equipment space is a natural progression for GrowLife and working
with My Fungi is the perfect illustration of how we are leveraging our long
history of cultivation expertise to bring innovative and high-demand products
to emerging markets,” said Marco Hegyi, CEO of GrowLife. “The founder of My
Fungi, Mr. Dave Auger, is a previous leader of our Canadian operations, and a
long-time friend of GrowLife. Dave has built a strong supply chain for
difficult to obtain equipment such as sterilized substrates which are required
for cultivating food and medicinal grade mushrooms. Having one of the strongest
and only supply chains of these products is a major differentiator for GrowLife
and creates a completely new opportunity for growth for our Company.”
“I am excited to be working with
GrowLife again,” stated Dave Auger, Founder of My Fungi . “Teaming up will
allow My Fungi to expand into the rapidly developing mushroom cultivation
markets of the United States. Sterilization is a significant pain point of
mushroom cultivators, working with GrowLife will ensure that anyone interested
in cultivating mushrooms will have access to the products and support needed to
get growing.”
Beyond the emerging science around
the medicinal benefits of mushrooms, mushrooms for use in food and wellness
products represents a global market size of $46.1 billion in 2020, with the US
being the second largest mushroom consumption market. While consumer demand for
quality mushrooms rises, the supply of necessary growing equipment is becoming
more constrained, fueled further by logistical issues impacting imports at US
Ports. The products that GrowLife will sell through this distribution agreement
are produced in North America, alleviating port issues, and stabilizing the
supply chain to meet this demand.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google
Podcasts and most audio platforms available.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big
Investing Ideas
Investorideas.com
publishes breaking stock news, third
party stock research , guest posts and original
articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and
IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor
Idea’s original branded content includes podcasts and columns : Crypto Corner , Play
by Play sports and stock news , Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast ,
Cleantech
and Climate Change , Exploring
Mining , Betting
on Gaming Stocks Podcast and the AI
Eye Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and
equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Thursday, 28 October 2021
Friday, 22 October 2021
Investor Ideas #Potcasts 608, #Cannabis News and #Stocks on the Move; Interview with President and CEO of RIV Capital (CSE: $RIV.C) (OTC: $CNPOF)
Investor Ideas #Potcasts 608, #Cannabis News and #Stocks on the Move; Interview with President and CEO of RIV Capital (CSE: $RIV.C) (OTC: $CNPOF)
Delta, Kelowna, BC, October 22, 2021 (Investorideas.com Newswire) www.Investoride, as.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/102221-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/10221RIV-CNPOF.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In today’s podcast
Investorideas interviews Narbe Alexandrian, President and CEO of RIV Capital Inc. (CSE: RIV) (OTC: CNPOF), where we discussed the companyès
transition from Canopy Rivers Inc. to RIV Capital, the companyès recent news
and investments as well as the investment opportunities being noticed right now
in the US cannabis space.
Discussing how
Canopy Rivers transitioned into RIV Capital, Narbe Alexandrian commented, “RIV
Captial started as Canopy Rivers back in 2017, and at the time we were the
venture capital arm of Canopy Growth. By late 2017 we spun off to become our
own entity but we were still controlled by Canopy Growth through multiple
voting shares. I joined the company the summer of 2018 and we took the company
public in the fall of 2018. BY January of 2019 I was promoted to President and
then CEO by May of 2019. Fast forwarding to that May of 2019, where in my new
role, everything I was seeing was pointing towards the US market. The market is
huge, it’s underserved, there is still a lot of stigma attached to what you can
do there.So I was trying everything I could to get more US exposure before
anybody was really talking about US exposure. However at the time we weren’t
able to go there because of Canopy Grwoth’s ties to the US legalization issues
in the US. Over the next 18 months we worked to really clean up shop by
unwinding deals and structures that were made while working on a deal to get us
to the US market.”
Alexandrian
continued, “In December 2020, and we closed this in February of 2021, we sold
the interest in three of our portfolio companies for, at closing it was 380
million CAD, part of that was cash and part of that was Canopy Growth shares.
We used a portion of that to buy out Canopy GFrowth’s position and another part
of that to pay off a liability that I inherited from my predecessors. So with a
chunk of cash and no control over us, we could finally get to the US market. AS
we were looking at different acquisitions and investments, Scotts Miracle Gro
reached out to us and that lead to the strategic investment they made on their
end.”
The
Hawthorne Collective, Inc., a cannabis-focused subsidiary of The Scotts Miracle-Gro Company (NYSE: SMG) purchased an unsecured convertible
note from RIV Capital for US$150 million back in August of 2021.
“The closing of the
investment from The Hawthorne Collective comes at a key moment for RIV
Capital,” said Narbé Alexandrian, President and CEO, RIV Capital. “The ongoing
uncertainty around the status of U.S. federal cannabis legalization continues
to sideline significant amounts of capital, creating attractive acquisition
opportunities in strategic markets. We believe we are well-positioned to
capitalize on these opportunities, given our strong balance sheet and
acquisition currency, and develop our operating and brand platform.”
Alexandrian went on
to discuss where he is seeing the largest opportunities in the US, mentioning
the advantages of limited license States as well as R & D potential.
When asked about
the continued risk in the US, Alexandrian commented, “I think the biggest risk
is regulatory risk. As an example, right now New York has 10 vertically
integrated licenses that have been given out. These licenses give anybody the
ability to cultivate, extract, process and manufacture as well as create their
own dispensaries to sell their product. Each one of these licenses is worth a
lof money. But what happens when the government comes in and says, hey we did
10 and now we are going to make it into 100, what happens to the value of these
original 10 licenses? So whenever we
look at these businesses, even though they are in a state with limited licenses
where you're going to reap the benefits for maybe 3 or 4 years, we stress test
these companies and say, what does it look like if things change and you look
more like California than New York and can you survive and can you pivot?”
Narbe Alexandrian
went on to discuss some of the other potential areas of investment within the
US space, how things have changed over the last two years, how things are
expected to continue to develop, realistic expectations for federal cannabis
reform within the US as well as potential risks and benefits of a far off
globalized cannabis industry.
To find out more
information about RIV Capital, click the link here.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more
Investorideas.com
podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google
Podcasts and most audio platforms available.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big
Investing Ideas
Investorideas.com
publishes breaking stock news, third
party stock research , guest posts and original
articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and
IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor
Idea’s original branded content includes podcasts and columns : Crypto Corner , Play
by Play sports and stock news , Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast ,
Cleantech
and Climate Change , Exploring
Mining , Betting
on Gaming Stocks Podcast and the AI
Eye Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
New #Stocks to Watch -Biotech (NasdaqGS: $ERAS) (Nasdaq: $TCRX) (Nasdaq: $HCWB), Mining (CSE: $GMR.C) (CSE: $ATHA.C) Cannabis (CSE: $XBRA.C)
New #Stocks to Watch -Biotech (NasdaqGS: $ERAS) (Nasdaq: $TCRX) (Nasdaq: $HCWB), Mining (CSE: $GMR.C) (CSE: $ATHA.C) Cannabis (CSE: $XBRA.C)
Point Roberts WA, Delta BC, October 22, 2021 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining and Cannabis. Today’s stocks have been added to our lists of free stock directories in each sector.
Read this in full at https://www.investorideas.com/news/2021/main/10221Stocks.asp
The newest biotech companies are all recent Nasdaq IPOs focusing on cancer therapies, kidney disease, Alzheimer’s, diseases of the skin and infectious diseases.
The latest mining companies are all CSE-listed with operations in North America.
The newest cannabis company is an international cannabis company that includes infused beverages.
New Stocks added to Biotech Stocks Directory:
Erasca, Inc. (NasdaqGS:ERAS) At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
TScan Therapeutics, Inc. (Nasdaq:TCRX) is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
HCW Biologics Inc. (Nasdaq: HCWB) is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation. The Company is developing novel immunotherapies designed to improve health by disrupting the link between chronic, low-grade inflammation and age-related diseases such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases and autoimmune diseases. HCW uses its TOBI™ discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties for the treatment of inflammaging. Two of HCW Biologics lead inventions via TOBI™ include molecules HCW9218 and HCW9302, both currently undergoing IND-enabling studies.
Imago BioSciences, Inc. (Nasdaq: IMGO) is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF.
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
Transcode Therapeutics, Inc. (Nasdaq: RNAZ) is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational immunotherapy drug, ACU193, a humanized monoclonal antibody that selectively targets toxic AβOs in a Phase I clinical trial involving early Alzheimer’s disease patients.
Dermata Therapeutics, Inc. (Nasdaq:DRMA) is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is currently under clinical development for the treatment of acne, psoriasis, and rosacea. Our second product candidate, DMT410, uses our Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California.
Eliem Therapeutics, Inc. (Nasdaq: ELYM) is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
Adagio Therapeutics, Inc. (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.
ABVC BIOPHARMA, INC. (Nasdaq: ABVC) is a clinical-stage biopharmaceutical company focused on development of therapeutic solutions in oncology/hematology, the central nervous system (CNS), ophthalmology, and medical devices related to these fields. Its current pipeline features six drugs and a medical device, ABV-1701/Vitargus®. For its drug products, it is focused on conducting proof-of-concept trials through Phase II of clinical development at world-famous research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct clinical trials through Phase III at various locations throughout the world.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra's lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.
DICE Therapeutics, Inc. (Nasdaq: DICE) is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
New stocks added to Mining Stocks Directory:
Brascan Gold Inc. (CSE: BRAS) is a gold exploration issuer based in Vancouver, BC. The Company holds an option over the Vulcan Property, located in the Fort Steele Mining Division in southeastern BC.
Gelum Resources Ltd. (CSE: GMR) is a company focused on mineral exploration in British Columbia. Its principal project is the Eldorado Gold Property located in the Bralorne-Bridge River Gold district in south-central British Columbia.
Athena Gold Corporation (CSE: ATHA) is engaged in the business of mineral exploration and the acquisition of mineral property assets. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Excelsior Springs Project, located in Esmeralda County, Nevada, approximately 45 miles southwest of Goldfield, Nevada.
New Stocks added to Cannabis Stocks Directory:
Xebra Brands Ltd. (CSE: XBRA) is an international cannabis cultivation and product company with global brands and intellectual property. Xebra’s products range from wellness to leisure, and include beverages.
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.
Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about advertising and guest posts
https://www.investorideas.com/Advertise/
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Subscribe to:
Posts (Atom)
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ... -
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T... -
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...